Analysts Issue Forecasts for APVO Q1 Earnings

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Investment analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Aptevo Therapeutics in a report released on Thursday, November 7th. Roth Capital analyst J. Aschoff forecasts that the biotechnology company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($2.97) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS and Q4 2025 earnings at ($0.25) EPS.

Several other research firms have also recently commented on APVO. Roth Mkm lowered their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd. StockNews.com assumed coverage on shares of Aptevo Therapeutics in a research note on Thursday, November 7th. They issued a “sell” rating on the stock.

Aptevo Therapeutics Price Performance

Shares of Aptevo Therapeutics stock opened at $0.29 on Monday. The firm has a 50 day simple moving average of $0.24 and a 200 day simple moving average of $0.46. Aptevo Therapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $10.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.